Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 40Colorectal Neoplasms 25Colonic Neoplasms 10Brain Neoplasms 8Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Rectal Neoplasms 5Skin Neoplasms 4Lung Neoplasms 3Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Digestive System Neoplasms 2Thyroid Neoplasms 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Solid Tumor 1Skin Diseases 1Recurrence 1Rectal Diseases 1Neurofibromatosis 1 1Multiple Myeloma 1Lymphatic Metastasis 1Leukemia, Hairy Cell 1Intestinal Neoplasms 1Intestinal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1

Interventions

encorafenib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced BRAF Mutant Cancers × encorafenib × Clear all
NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
17 enrolled 9 charts

Advanced BRAF Mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡